Literature DB >> 22805761

Bone turnover in hyperparathyroidism.

Katharina Kerschan-Schindl1.   

Abstract

A narrow serum calcium level which is essential for many metabolic processes is regulated by the calcium-sensing receptor which regulates parathyroid hormone (PTH) release. Primary hyperparathyroidism is supposed to be the third most common endocrine disorder. Besides nephrolithiasis and an increased incidence of cardiovascular symptoms it is associated with bone loss and an increased risk of fracture. Several different classical bone turnover markers have been shown to be increased. However, there are many uncertainties in pathophysiology of PHPT. Hardly any conclusive data exist on the RANK (receptor activator of nuclear factor-kB)/RANKL (receptor activator of nuclear factor-kB ligand)/OPG (osteoprotegerin) system, cathepsin K, sclerostin, FGF-23 (Fibroblast growth factor-23), Klotho, and DKK 1 (Dickkopf 1) in patients suffering from PHPT.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22805761     DOI： 10.1007/s10354-012-0125-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  49 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

2.  Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy.

Authors:  P Christiansen; T Steiniche; K Brixen; I Hessov; F Melsen; L Heickendorff; L Mosekilde
Journal:  Bone       Date:  1999-08       Impact factor: 4.398

3.  Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover.

Authors:  V Carnevale; M T Pacitti; M Pileri; F Paglia; A Scillitani; S Dionisi; P Caravella; E Romagnoli; S Minisola
Journal:  J Endocrinol Invest       Date:  2001-09       Impact factor: 4.256

4.  Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.

Authors:  H Kaji; Y Imanishi; T Sugimoto; S Seino
Journal:  Exp Clin Endocrinol Diabetes       Date:  2011-06-10       Impact factor: 2.949

Review 5.  Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.

Authors:  P Lips
Journal:  Endocr Rev       Date:  2001-08       Impact factor: 19.871

6.  Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Authors:  Aliya A Khan; John P Bilezikian; Annie W C Kung; Mustafa M Ahmed; Sacha J Dubois; Andrew Y Y Ho; Debra Schussheim; Mishaela R Rubin; Atif M Shaikh; Shonni J Silverberg; Timothy I Standish; Zareen Syed; Zeba A Syed
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

7.  FGF-23 is elevated by chronic hyperphosphatemia.

Authors:  A Gupta; K Winer; M J Econs; S J Marx; M T Collins
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

8.  Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.

Authors:  C Y Guo; W E Thomas; A W al-Dehaimi; A M Assiri; R Eastell
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

9.  Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.

Authors:  Takehisa Kawata; Yasuo Imanishi; Keisuke Kobayashi; Takami Miki; Andrew Arnold; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

10.  Control of bone mass and remodeling by PTH receptor signaling in osteocytes.

Authors:  Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240
View more
  2 in total

1.  Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Martin B Niederle; Ursula Foeger-Samwald; Philipp Riss; Andreas Selberherr; Christian Scheuba; Peter Pietschmann; Bruno Niederle; Katharina Kerschan-Schindl
Journal:  Langenbecks Arch Surg       Date:  2019-08-26       Impact factor: 3.445

2.  Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model.

Authors:  Yuki Nagata; Yasuo Imanishi; Tomomi Tateishi; Daichi Miyaoka; Masafumi Kurajoh; Andrew Arnold; Masanori Emoto
Journal:  J Endocr Soc       Date:  2022-02-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.